• Labcorp reaffirmed 2026 guidance: revenue USD 14.71-14.83 billion, up 5.4%-6.3% from 2025 revenue USD 13.95 billion.
• Adjusted EPS forecast held at USD 18.1-18.55.
• Free cash flow outlook maintained at USD 1.24-1.36 billion.
• Diagnostics revenue seen at USD 11.45-11.53 billion; Biopharma Laboratory Services at USD 3.27-3.3 billion.
• Long-term outlook through 2029: revenue CAGR 5%-8%; adjusted EPS CAGR 8.5%-11.5%; adjusted operating margin to expand 75-150 bps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609100700PR_NEWS_USPR_____DC44316) on September 10, 2026, and is solely responsible for the information contained therein.